Nobilon to co-ordinate FluVac project

Dutch biopharmaceutical firm Nobilon International BV says that, in collaboration with parent organization Organon, it has been chosen to coordinate a joint development effort focused on the creation of a novel pandemic influenza vaccine. The project, known as FluVac, will bring together a consortium of experts in the field of human virus research and vaccine development, and has been awarded a 3.5 million-euro ($4.9 million) grant by the European Union.

Organizations participating in the project include the UK firms Protherics and Retroscreen Virology, the Erasmus Medical Center in the Netherlands and Iceland's Landspitali University Hospital.